Journal of Heart and Lung Transplantation最新文献

{"title":"In Memoriam - Professor Allan R Glanville, Past President ISHLT.","authors":"Peter Mark Anthony Hopkins","doi":"10.1016/j.healun.2025.02.004","DOIUrl":"https://doi.org/10.1016/j.healun.2025.02.004","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Living donor lobar lung transplantation in children: An impressive Japanese cohort and worldwide implications.","authors":"Nicholas Avdimiretz, Christian Benden","doi":"10.1016/j.healun.2025.02.003","DOIUrl":"10.1016/j.healun.2025.02.003","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable left ventricular assist device in donation after circulatory death heart transplantation.","authors":"Yeahwa Hong, Umar Nasim, Nidhi Iyanna, Ander Dorken-Gallastegi, Mary E Keebler, Edward T Horn, Gavin W Hickey, David J Kaczorowski","doi":"10.1016/j.healun.2025.01.016","DOIUrl":"10.1016/j.healun.2025.01.016","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates outcomes following donation after circulatory death (DCD) heart transplantation in recipients with a durable left ventricular assist device (LVAD).</p><p><strong>Methods: </strong>The UNOS registry was queried to analyze adult recipients of isolated DCD heart transplantation between 1/1/2019-3/31/2023. The recipients were stratified by durable LVAD use as a bridge to transplantation. The primary outcome was 1-year post-transplant survival. Sub-group analyses were conducted to evaluate the effects of transplant status, device type, and donor type on 1-year survival.</p><p><strong>Results: </strong>A total of 703 recipients were included, of which 219 (31.2%) recipients were bridged with a durable LVAD. The recipients of DCD hearts with durable LVADs had significantly lower 1-year post-transplant survival compared to those without durable LVADs (88.4% vs. 93.6%, p=0.017). Among the recipients bridged with durable LVADs, status 4 recipients had significantly improved 1-year survival compared to statuses 2 and 3 recipients, similar to those without durable LVADs. Furthermore, the recipients with HeartMate II and HeartMate 3 had improved survival compared to those with the HeartWare HVAD, similar to those without durable LVADs. Lastly, the DCD and DBD recipients with durable LVADs had comparable 1-year survival (88.4% vs. 89.0%, p=0.763).</p><p><strong>Conclusions: </strong>Recipients of DCD hearts bridged to transplantation with a durable LVAD exhibit reduced early post-transplant survival compared to those without a durable LVAD. However, clinical acuity and device type significantly influence post-transplant outcomes in this vulnerable population. Despite this, candidates with a durable LVAD can safely undergo DCD heart transplantation, achieving early post-transplant survival comparable to those of DBD heart transplantation.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right ventricular-pulmonary arterial coupling in schistosomiasis associated pulmonary arterial hypertension.","authors":"Jose Leonidas Alves-Jr, Eduardo Leite Vieira Costa, Susana Hoette, Caio Julio Cesar Dos Santos Fernandes, Henrique Barbosa Ribeiro, Alexandre Antonio Cunha Abizaid, Marcela Araújo Castro, Bruna Mamprim Piloto, Pedro Alves Lemos, Carlos Viana Poyares Jardim, Ryan J Tedford, Rogerio Souza","doi":"10.1016/j.healun.2025.01.018","DOIUrl":"10.1016/j.healun.2025.01.018","url":null,"abstract":"<p><strong>Background: </strong>Schistosomiasis associated pulmonary arterial hypertension (Sch-PAH) is a highly relevant form of pulmonary hypertension, particularly in developing countries. Compared with idiopathic pulmonary arterial hypertension (IPAH), Sch-PAH has a better prognosis, though without identified mechanisms that justify this clinical course. Right ventricular-arterial pulmonary (RV-PA) coupling, expressed by the relationship between right ventricular contractility and afterload, has been studied as a potential marker of cardiac response to pulmonary vascular disease. However, there are no studies evaluating RV-PA coupling in Sch-PAH.</p><p><strong>Methods: </strong>Retrospective cohort including patients diagnosed with Sch-PAH or IPAH who underwent right heart catheterization (RHC) at our institution from 2013 to 2018. Clinical and hemodynamic characteristics were reviewed and, by means of the recorded and digitized RHC pressure curves, right ventricular maximum isovolumic pressure (Pmaxiso) was estimated through the single-beat method to calculate right ventricular elastance at the end systole (Ees). The RV-PA was expressed by the Ees and the pulmonary artery elastance (Ea) ratio.</p><p><strong>Results: </strong>A total of 101 patients were included (33 with Sch-PAH and 68 with IPAH). Sch-PAH patients were older (55.5 ± 15.1 vs 42.7 ± 15.2; p <0.001) with no significant difference in terms of traditional hemodynamics; nevertheless, Sch-PAH patients had better survival (p=0.031). Patients with Sch-PAH showed higher RV-PA coupling (0.95±0,58 vs 0.67±0.41; p = 0.004), higher Ees (2.07±1.65 vs 1.33±0.91; p = 0.005) without any difference in Pmaxiso and Ea compared with IPAH. At univariate analysis, RV-PA coupling was associated with survival. The RV-PA coupling remained an independent prognostic marker in the multivariable analysis adjusted for the type of pulmonary arterial hypertension (p = 0.030; HR = 0.287; 95% CI, 0.093-0.883).</p><p><strong>Conclusions: </strong>RV-PA coupling is better preserved in Sch-PAH patients and is significantly associated with survival, suggesting that the right ventricular response to the increased afterload in Sch-PAH might represent an important pathophysiological mechanism that could explain the better clinical course observed in this relevant form of PAH.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Octo- and nonagenarian donors in lung transplantation: A dual center experience.","authors":"Cedric Vanluyten, Charlotte Schoenaers, René Novysedlák, Jan Van Slambrouck, Christelle Vandervelde, Hanne Beeckmans, Jan Havlin, Arne P Neyrinck, Piet Lormans, Karen Denaux, Dirk E Van Raemdonck, Robin Vos, Robert Lischke, Laurens J Ceulemans","doi":"10.1016/j.healun.2025.02.002","DOIUrl":"10.1016/j.healun.2025.02.002","url":null,"abstract":"<p><p>The maximal donor age for lung transplantation (LTx) remains controversial, despite favorable outcomes with donors ≥70 years. We report our experience with LTx from donors ≥80 years. Donor/recipient characteristics and short-term postoperative outcome were retrospectively analyzed across two centers between 2016 and 2023. Seventeen patients underwent single (n=2) or double (n=15) LTx from octo- or nonagenarian donors with a median age of 83 years (range 80-94). Most donors were non-smoking females with intracerebral bleeding. Last donor PaO₂/FiO₂ ratio was 440 mmHg. Three recipients developed PGD3 at 72 h. Median ICU and hospital stay were 11 and 29 days, respectively. Five patients showed minimal (A1) ACR at one month post-LTx. Two patients developed CLAD. One- and three-year survival rates were 84% and 70%. Our case series indicates that LTx from well-selected octo- and nonagenarian donors is a valuable option to expand the donor pool.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Comment on \"Immunomodulatory soluble HLA-G and HLA-E are associated with rapidly deteriorating CLAD and HCMV viremia after lung transplantation\".","authors":"Hannes Vietzen","doi":"10.1016/j.healun.2025.01.022","DOIUrl":"10.1016/j.healun.2025.01.022","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The steep cliff of renal failure after heart transplant: Is a safety net enough to rescue those who fall?","authors":"Amrut V Ambardekar, Laura L Peters","doi":"10.1016/j.healun.2025.01.017","DOIUrl":"10.1016/j.healun.2025.01.017","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Immunomodulatory soluble HLA-G and HLA-E are associated with rapidly deteriorating CLAD and HCMV viremia after lung transplantation\".","authors":"Olivier Brugière, Dora Dreyfuss, Sophie Rong, Joel LeMaoult, Nathalie Rouas-Freiss","doi":"10.1016/j.healun.2025.01.005","DOIUrl":"https://doi.org/10.1016/j.healun.2025.01.005","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precise monitoring of transpulmonic resistance in bridge-to-transplant patients supported by the Aeson total artificial heart.","authors":"Yuriy Pya, Makhabbat Bekbossynova, Assel Medressova, Christian Latremouille, Piet Jansen, Ainur Tauyekelova, Rymbay Kaliyev, Saltanat Jetybayeva, Luke A Ziegler, Indranee Rajapreyar, Jesus Eduardo Rame","doi":"10.1016/j.healun.2025.02.001","DOIUrl":"10.1016/j.healun.2025.02.001","url":null,"abstract":"<p><p>The Aeson total artificial heart (TAH) features embedded pressure sensors for flow autoregulation, which can also be used to estimate pressure gradients. In this bridge-to-transplant study, right and left ventricular pressure data and pump output from the TAH were analyzed to estimate transpulmonic resistance (eTPR) every 30 days. Three patients (aged 60, 35, and 54) with preimplant pulmonary vascular resistance of 7.0, 3.2, and 7.1 Wood Units, respectively, were supported by the TAH at pump outputs of 4.5 to 6.5 liter/min. All showed significant eTPR reductions (1.4-1.5 Wood Units) and received donor hearts after 243, 155, and 109 days of support. Two patients underwent successful transplants without complications; one died post transplant from pneumonia and multiorgan failure. The Aeson TAH's eTPR monitoring system offers a promising, noninvasive approach to managing pulmonary hypertension and assessing transplant eligibility in real time.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surveillance donor-specific antibody and pathologic antibody-mediated rejection testing in heart transplant patients in the contemporary era.","authors":"Vincenzo Cusi, Ashley Cardenas, Yuko Tada, Florin Vaida, Nicholas Wettersten, Jennifer Chak, Victor Pretorius, Marcus Anthony Urey, Gerald P Morris, Grace Lin, Paul J Kim","doi":"10.1016/j.healun.2025.01.019","DOIUrl":"10.1016/j.healun.2025.01.019","url":null,"abstract":"<p><strong>Background: </strong>Surveillance donor-specific antibody (DSA) and pathologic antibody-mediated rejection (pAMR) testing is recommended in the first year after heart transplantation (HTx) in adult patients. Whether pAMR testing adds prognostic information to contemporary DSA testing has not been fully studied.</p><p><strong>Methods: </strong>This was a single-center study of consecutive endomyocardial biopsies (EMB) performed between November 2010 and February 2023 in adult HTx patients. The primary objective was to evaluate whether pAMR testing contributes additional information to DSA testing to better predict overall survival. Secondary end-points included cardiac survival and allograft dysfunction.</p><p><strong>Results: </strong>A total of 6,033 EMBs from 544 HTx patients were reviewed for the study. The pAMR+/DSA+ patients had significantly lower overall (p_c = 0.013) and cardiac survival (p_c = 0.002), while the pAMR+/DSA- and pAMR-/DSA+ patients showed no difference in either outcome compared to the pAMR-/DSA- group. We found significantly lower overall survival in pAMR+/DSA+ patients with allograft dysfunction (p_c < 0.001) but not in pAMR+/DSA+ patients without allograft dysfunction (p_c = 0.569), when compared to the pAMR-/DSA- without allograft dysfunction group. The pAMR+/DSA+ patients with cardiac allograft dysfunction accounted for 18% of deaths or cardiac retransplants while only representing 4% of the HTx cohort. Moderate or severe primary graft dysfunction (PGD) also was a novel risk factor for the development of de novo DSAs (dnDSA) by 4 weeks post-HTx (p = 0.025).</p><p><strong>Conclusions: </strong>Surveillance DSA testing may effectively identify high-risk pAMR+ patients. Earlier DSA testing at 10 to 14 days post-HTx should also be considered in moderate or severe PGD patients.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}